ICICI Bank Ltd. (NYSE:IBN)

ICICI Bank offers a wide range of banking products and services to corporate and retail customers through a variety of delivery channels.

ICICI Bank Ltd. (NYSE:IBN)’s Financial Overview

ICICI Bank Ltd. (NYSE:IBN) surged 0.94% yesterday to close its trading session at $7.53. The company has 1 year Price Target of $10.3. ICICI Bank Ltd. has 52-Week high of $8.8 and 52-Week Low of $5.15. The stock touched its 52-Week High on Nov 10, 2016 and 52-Week Low on Feb 25, 2016. The stock traded with the volume of 8.25 Million shares yesterday. The firm shows the market capitalization of $21.97 Billion.

The firm is trading with SMA20 of -6.5 Percent, SMA50 of -5.19 Percent and SMA200 of 3.69 percent. ICICI Bank Ltd. has P/S value of 5.02 while its P/B value stands at 0. Similarly, the company has Return on Assets of 0 percent, Return on Equity of 0 percent and Return on Investment of 4.5 Percent. The company shows Gross Margin and Operating Margin of 0 percent and 0 percent respectively.

Many brokerage firms are involved in issuing their ratings on ICICI Bank Ltd. (NYSE:IBN). On 24-Oct-16 Goldman Upgrade ICICI Bank Ltd. Stock  to Buy. Another firm also rated the stock on 16-Jun-16 where JP Morgan Downgrade the stock to Neutral.

The Stock currently has Analyst’ mean Recommendation of 1 where the scale is from 1 to 5, 1 means Strong Buy and 5 means Sell.

The 46 analysts offering 12-month price forecasts for ICICI Bank have a median target of 9.54, with a high estimate of 11.21 and a low estimate of 6.50. The median estimate represents a +26.75% increase from the last price of 7.53.

Our vendor, Zacks Investment Research, hasn’t provided us with the upcoming earnings report date.

EnteroMedics Inc. (NASDAQ:ETRM)

EnteroMedics Inc. was established to develop and commercialize a new therapeutic platform for treating a wide range of acute and chronic diseases that are mediated by the vagal nerves. Due to the large unmet need for more effective surgical management of obesity, and following an in-depth analysis of how the vagus nerve affects food intake and processing, EnteroMedics has selected obesity management as its primary focus.

EnteroMedics Inc. (NASDAQ:ETRM)’s Financial Outlook

The 2 analysts offering 12-month price forecasts for EnteroMedics Inc have a median target of 1.10, with a high estimate of 2.00 and a low estimate of 0.20. The median estimate represents a +1,517.65% increase from the last price of 0.07.

Our vendor, Zacks Investment Research, hasn’t provided us with the upcoming earnings report date.

According to Zacks Investment Research, EnteroMedics Inc. has a Consensus Recommendation of 2. (The Scale is from 1-5 where 1 means Strong Buy and 5 means Strong Sell).

The Stock fell -4.63% and closed its last trading session at $0.07. The company has the market capitalization of $7.67 Million. The stock has 52-week high of $2.7 and 52-Week low of $0.04. The firm touched its 52-Week high on Dec 31, 2015 and 52-Week low on Nov 22, 2016. The company has volume of 8.23 Million shares. The company has a total of 112.86 Million shares outstanding.

EnteroMedics Inc. (NASDAQ:ETRM) in the last quarter reported its actual EPS of $-0.17/share where the analyst estimated EPS was $-0.5/share. The difference between the actual and Estimated EPS is $0.33. This shows a surprise factor of 66 percent.

The company has YTD performance of -96.51 percent. Beta for EnteroMedics Inc. stands at 2.24 while its ATR (average true range) is 0.02. The company has Weekly Volatility of 49.25%% and Monthly Volatility of 28.25%%.

EnteroMedics Inc. has distance from 20-day Simple Moving Average (SMA20) of 2.36%, Distance from 50-Day Simple Moving Average of -31.1 percent and Distance from 200-Day Simple Moving Average of -85.31%.

The Company currently has ROA (Return on Assets) of -197.6 percent, Return on Equity (ROE) of 0 Percent and Return on Investment (ROI) of -568.7% with Gross margin of 48 percent and Operating & Profit margin of 0% and 0% respectively.